PARIS, April 28, 2022 - PRESS RELEASE
Discngine, a fast-growing R&D and lab informatics solutions and services company, today announced that Confo Therapeutics (Confo), a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), will use its 3decision® software to facilitate their structure-based drug design programs.
Discngine’s 3decision® software will enable Confo to centralize all available GPCR structural knowledge in one unique platform by streamlining the registration and management of both publicly available PDB structures and their novel, unpublished structures. 3decision®’s visualization and search tools will also make it more straightforward for Confo’s experts in GPCRs, structural biology, computer-aided drug design, and medicinal chemistry to derive further unprecedented structural insights that have the potential to accelerate their drug discovery projects.
Furthermore, Confo and Discngine will collaborate on new developments that will further enhance the 3decision® platform. One of the priorities of 2022 is to enable Protein-Protein Interaction (PPI) analysis capabilities in 3decision®. These types of insights would identify, analyze, and visualize GPCR interactions with G-proteins and ConfoBodies®* as well as help to augment the design process of GPCR-targeting biologics.
3decision® is a web-based protein structure repository with extended features for categorizing, analyzing, and visualizing protein-ligand structural data. Its main strength lies in the automatic transformation of the structural data generated over time into valuable knowledge, easily accessible by scientists for convenient structure-based discoveries. In addition, 3decision® offers a possibility to navigate through the growing amount of complex structural data and increase the efficiency of the idea generation and design cycle.
“At Confo we produce many active state structures using our unique platform. This collaboration with Discngine will help us to derive the most insights from our structures to maximize their impact on our drug discovery programs.”
“Technological advancements continue to produce complex structural data at a high pace. Our 3decision® platform enables scientists to turn challenges in structural data management into opportunities for rational drug discovery due to streamlined structural data registration, fast navigation and advanced analytics.”
3decision® platform: www.3decision.discngine.com
* Confobodies® are conformation-stabilizing immunoglobulin single variable domains. They are ideal tools to selectively stabilize desired conformational states of conformationally complex (membrane) proteins such as GPCRs, and G protein complexes thereof.